Peptides for athletic performance — what research has explored across recovery, hypertrophy, and endurance

This is how most people enter the performance peptide conversation. Not through a physician's office, not through a clinical trial — through a forum post by someone describing outcomes that mainstream sports medicine can't reliably reproduce. The recovery time for soft tissue injuries in particular is one of the most unsatisfying realities of athletic medicine: we can scan it, we can stage it, and then we can largely wait. The biological case for tissue-repair peptides is compelling precisely because of that gap. Whether the human evidence has caught up with the animal data is a different question, and it's one this piece tries to answer honestly.

A prerequisite for any serious discussion of athletic performance peptides is the doping context. The World Anti-Doping Agency (WADA) maintains a prohibited list that is updated annually. Many of the compounds in this landscape — BPC-157, TB-500, Follistatin, IGF-1 variants, MGF, several GH secretagogues — are on that list or prohibited under broader category bans (peptide hormones, growth factors, and related substances). For competitive athletes in any WADA-compliant sport, use of these compounds is not a gray area: it is a disqualification risk, regardless of therapeutic intent, regardless of prescription status, regardless of what the evidence says. That is the regulatory reality, and it applies before any other consideration.

BPC-157 is the tissue-repair compound with the broadest and deepest research base in athletic performance contexts. Its history in gut research is discussed elsewhere, but the same mechanisms that support gut mucosal healing — VEGF-driven angiogenesis, growth hormone receptor sensitization, anti-inflammatory cytokine modulation — have been extensively studied in musculoskeletal models. Rodent research has explored BPC-157 in tendon healing, ligament repair after surgical transection, muscle crush injuries, and bone fracture healing, consistently showing accelerated recovery compared to controls. The tendon data is particularly striking: several studies have demonstrated dramatically faster healing of surgically cut Achilles tendons in rats treated with BPC-157 versus untreated controls, with histological examination showing more organized collagen architecture in treated tissue.

The human clinical picture for BPC-157 in sports medicine is sparse. There are no published Phase III trials for musculoskeletal applications. There are case series and clinical observations from practitioners who have used it, and a significant amount of user-reported experience in athletic communities, but randomized controlled human trials demonstrating efficacy for soft tissue repair specifically are not yet in the literature. BPC-157 is not FDA-approved and exists in the United States as a compounded peptide. WADA prohibits it. The preclinical evidence is genuine and mechanistically sound; the human evidence gap is real.

TB-500 is a synthetic fragment of Thymosin Beta-4, a protein involved in actin polymerization and cell migration — processes fundamental to tissue repair and regeneration. Thymosin Beta-4 is produced at injury sites and facilitates the migration of keratinocytes, endothelial cells, and muscle progenitor cells to damaged tissue. TB-500 was developed as a more stable, more bioavailable fragment of the full protein. Research has explored it in cardiac muscle repair after myocardial infarction in animal models — where some of the most impressive regenerative data has come from — and in equine tendon injury, where it has been used in veterinary settings. The human sports medicine data is limited. WADA prohibits TB-500.

The muscle hypertrophy angle brings in several compounds with distinct mechanisms. Mechano growth factor, or MGF, is a splice variant of IGF-1 (insulin-like growth factor 1) that is expressed locally in muscle tissue in response to mechanical loading — that is, in response to resistance training. MGF activates muscle satellite cells, which are the resident stem cells in muscle tissue that fuse with existing muscle fibers to add contractile units after training. PEG-MGF is a PEGylated version of MGF, modified to increase its circulating half-life significantly. The hypothesis is that exogenous MGF or PEG-MGF could amplify the satellite cell activation that training naturally triggers, accelerating muscle protein accretion. The preclinical data in rodent models is promising. Human trials are essentially absent. WADA prohibits both.

Follistatin 344 operates through a different mechanism: it inhibits myostatin, a protein that limits skeletal muscle growth. The myostatin pathway functions as a brake on muscle mass — individuals born with myostatin gene mutations develop dramatically elevated muscle mass, a phenotype observed in cattle, mice, and in rare human cases. Follistatin, by binding and neutralizing myostatin, releases that brake. In animal models, follistatin overexpression produces extraordinary muscle hypertrophy. Gene therapy approaches using follistatin have been explored in duchenne muscular dystrophy, where the evidence has clinical relevance. The use of exogenous Follistatin 344 by athletes for hypertrophy sits at the far edge of available evidence: the research is compelling in principle, the delivery challenges for a peptide of this size are significant, and the safety in healthy humans has not been characterized. WADA prohibits it.

IGF-1 LR3 and IGF-1 DES are modified forms of insulin-like growth factor 1 designed for increased potency and/or extended half-life. IGF-1 itself is a growth factor central to muscle protein synthesis, nutrient partitioning, and tissue repair downstream of growth hormone signaling. The modified forms have circulated in bodybuilding communities for decades, often in the context of post-cycle therapy after anabolic steroid use, and have generated significant user-reported data. The clinical research on these specific variants for athletic performance in healthy individuals is thin; the safety and dose-response characterization is essentially from community use rather than controlled studies. Elevated IGF-1 signaling has potential oncological implications that have not been studied in this context. WADA prohibits IGF-1 variants.

The GH secretagogue category — compounds that stimulate endogenous growth hormone release — has been more extensively studied and includes compounds that have entered clinical development. Sermorelin, a GHRH analog, was FDA-approved for growth hormone deficiency in children and has been used in adults off-label for GH support. Ipamorelin is a selective GHRH receptor agonist that stimulates clean GH pulses without the cortisol and prolactin side effects of older secretagogues. CJC-1295 extends the half-life of GHRH signaling via a drug affinity complex. MK-677 (ibutamoren) is a non-peptide ghrelin mimetic that stimulates GH release and has been studied in Phase II trials for muscle wasting and GH deficiency. Hexarelin is an older growth hormone secretagogue with more side-effect burden.

In athletic performance contexts, GH secretagogues are researched for their effects on body composition — reduced fat mass, preserved or slightly increased lean mass — and on recovery, through GH's roles in tissue repair and protein synthesis. The effect sizes for body composition are meaningful but less dramatic than direct anabolic compounds; the trade-off is that stimulating endogenous GH is more physiologically controlled than exogenous GH administration. WADA prohibits GH secretagogues and peptide hormones in this category regardless of mechanism or prescription status.

The endurance and metabolic flexibility angle is perhaps the most scientifically novel part of this landscape. MOTS-c, the mitochondria-derived peptide, has been called an exercise mimetic because its effects — AMPK activation, improved fatty acid oxidation, enhanced insulin sensitivity — overlap with the metabolic adaptations produced by endurance training. Research in mice showed that MOTS-c injections improved running capacity and metabolic markers in aged animals in ways that suggested mitochondrial support independent of training volume. AICAR, an AMPK activator, produced similar findings in rodent models that generated significant media coverage as a "couch potato drug." Neither MOTS-c nor AICAR has been shown to produce meaningful endurance or performance improvements in trained healthy humans. WADA prohibits AICAR.

AOD-9604, the GH fragment discussed in the fat-loss context, has been explored in athletic settings for its proposed visceral fat mobilization effects. Tesamorelin, with its FDA-approved indication for lipodystrophy, is similarly relevant for fat partitioning — the ratio of fat to lean mass — in athletic body composition contexts. Both are discussed here in the context of the body-composition angle of athletic performance rather than direct performance enhancement.

The body of rodent data supporting several compounds in this landscape is genuinely impressive in terms of effect size and mechanistic consistency. The problem of translation from rodent to human in musculoskeletal research specifically is well-documented: rodents heal differently from humans, have different connective tissue biology, and run their lives at a metabolic rate that makes healing and muscle-building data difficult to extrapolate. Several compounds that showed substantial promise in rodent muscle studies have failed to produce the same effects in human trials. This does not mean the mechanisms are wrong. It means that demonstration in animals is not demonstration in humans, and the distinction matters clinically.

The foundational role of progressive overload, protein intake, sleep quality, and training periodization in athletic performance cannot be overstated. These interventions have the largest and most consistent evidence base for both performance and recovery. Adequate protein intake — in the range of 1.6 to 2.2 grams per kilogram of body weight for strength athletes — is among the most evidence-supported interventions for muscle hypertrophy and recovery. Sleep is when growth hormone is primarily released and when muscle protein synthesis is highest. Strategic periodization — the structured alternation of loading and recovery — prevents the overuse injuries that generate the demand for repair compounds in the first place. None of these are as compelling in online forums as a novel injectable, but the evidence differential is significant.

The doping question cannot be tucked into a footnote. Competitive athletes who use WADA-prohibited compounds — regardless of prescription, regardless of clinical supervision, regardless of the evidence basis for any individual compound — face disqualification and career consequences. The anti-doping framework doesn't distinguish between therapeutic intent and performance intent. It doesn't distinguish between compounds with robust clinical evidence and compounds used on speculation. The prohibited list is the prohibited list. Any athlete in a tested sport who is considering peptides should understand this before any clinical conversation begins.

For non-competitive athletes, the conversation is different in its doping dimension but not in its clinical dimension. If you are considering peptides in the context of injury recovery or body composition and you are working with a prescribing provider, the relevant questions are: which compounds have the most relevant evidence for your specific situation, what is the risk profile given what is and isn't known about human safety, and how does this fit into an overall approach that includes the foundational interventions? That evaluation requires a provider who understands both sports medicine and the peptide landscape — not a provider who dispenses one or the other in isolation.